医药稳健科研股策略:年化收益率（22.47%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 41.67%
- 年化收益率: 22.47%
- 基准收益率: 4.99%
- 阿尔法: 0.22
- 夏普比率: 0.77
- 最大回撤: 22.06%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2025-06-26 | 亚宝药业(600351.SH) | 5.8472509485938 | 78230 | 37 | 6.03 | 471726.9 | 14296.46/3.125% |
| 2025-06-26 | 国药现代(600420.SH) | 10.299906 | 44700 | 37 | 10.65 | 476055 | 15649.2/3.399% |
| 2025-06-26 | 浙江医药(600216.SH) | 13.997300472281 | 32500 | 67 | 14.33 | 465725 | 10812.73/2.377% |
| 2025-06-25 | 亚宝药业(600351.SH) | 5.8472509485938 | 78230 | 36 | 6.07 | 474856.1 | 17425.66/3.809% |
| 2025-06-25 | 国药现代(600420.SH) | 10.299906 | 44700 | 36 | 10.67 | 476949 | 16543.2/3.593% |
| 2025-06-25 | 浙江医药(600216.SH) | 13.997300472281 | 32500 | 66 | 14.43 | 468975 | 14062.73/3.091% |
| 2025-06-24 | 亚宝药业(600351.SH) | 5.8472509485938 | 78330 | 35 | 6.07 | 475463.1 | 17447.93/3.809% |
| 2025-06-24 | 国药现代(600420.SH) | 10.299906 | 44900 | 35 | 10.64 | 477736 | 15270.22/3.302% |
| 2025-06-24 | 浙江医药(600216.SH) | 13.995718066331 | 32400 | 65 | 14.47 | 468828 | 15366.73/3.389% |
| 2025-06-23 | 亚宝药业(600351.SH) | 5.8472509485938 | 78330 | 34 | 5.98 | 468413.4 | 10398.23/2.27% |
交易详情
| 2025-06-25 | 浙江医药(600216.SH) | 买 | 100 | 14.46 | 1446 | ¥5 | 0 |
| 2025-06-25 | 国药现代(600420.SH) | 卖 | -200 | 10.65 | -2130 | ¥7.13 | 70.02 |
| 2025-06-25 | 亚宝药业(600351.SH) | 卖 | -100 | 6.08 | -608 | ¥5.61 | 23.27 |
| 2025-06-18 | 浙江医药(600216.SH) | 买 | 200 | 14.77 | 2954 | ¥5 | 0 |
| 2025-06-18 | 亚宝药业(600351.SH) | 买 | 900 | 6.15 | 5535 | ¥5 | 0 |
| 2025-06-11 | 国药现代(600420.SH) | 卖 | -100 | 11 | -1100 | ¥6.1 | 70.01 |
| 2025-06-11 | 亚宝药业(600351.SH) | 卖 | -1400 | 6.37 | -8918 | ¥13.92 | 736.87 |
| 2025-06-04 | 浙江医药(600216.SH) | 卖 | -1500 | 15.12 | -22680 | ¥29.48 | 1693.87 |
| 2025-06-04 | 国药现代(600420.SH) | 买 | 1200 | 10.9 | 13080 | ¥5 | 0 |
| 2025-06-04 | 亚宝药业(600351.SH) | 买 | 2100 | 6.26 | 13146 | ¥5 | 0 |
